Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18566580 | 1.00 | ADORA1 (0.36) | ADORA1SIGMAR1CTSBCTSSCTSK | |
| SCHEMBL47599 | 1.00 | ADORA1 (0.36) | ADORA1SIGMAR1CTSBCTSSCTSK | |
| SCHEMBL47603 | 1.00 | ADORA1 (0.36) | ADORA1SIGMAR1CTSBCTSSCTSK | |
| SCHEMBL47607 | 0.91 | SIGMAR1 (0.40) | ADORA1SIGMAR1CTSBCTSSCTSK | |
| SCHEMBL47637 | 0.91 | SIGMAR1 (0.40) | ADORA1SIGMAR1CTSBCTSSCTSK | |
| SCHEMBL47642 | 0.86 | KMT2A (0.35) | ADORA1SIGMAR1CTSBCTSSCTSK | |
| SCHEMBL47611 | 0.86 | KMT2A (0.35) | ADORA1SIGMAR1CTSBCTSSCTSK | |
| SCHEMBL47614 | 0.86 | CTSB (0.34) | CTSBCTSSCTSK | |
| SCHEMBL47620 | 0.86 | CTSB (0.34) | CTSBCTSSCTSK | |
| SCHEMBL18780914 | 0.84 | ADORA1 (0.35) | ADORA1SIGMAR1CTSBCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058084-A1 | Interferon Alpha Carrier Prodrugs | ASCENDIS PHARMA AS (DK) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058084-A1 | Interferon Alpha Carrier Prodrugs | IFNG, IFNAR1, IRF3 | ADORA1 884/4885SIGMAR1 157/4885CTSB 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.